ATRC:NSD-AtriCure Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 41.34

Change

-2.04 (-4.70)%

Market Cap

USD 1.91B

Volume

0.24M

Avg Analyst Target

USD 82.00 (+98.36%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AtriCure Inc (ATRC) Stock Analysis:
Based on the AtriCure Inc stock forecasts from 3 analysts, the average analyst target price for AtriCure Inc is USD 82.00 over the next 12 months. AtriCure Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of AtriCure Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, AtriCure Inc’s stock price was USD 41.34. AtriCure Inc’s stock price has changed by -4.04% over the past week, -29.07% over the past month and -42.92% over the last year.

About

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-24 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ISRG Intuitive Surgical Inc

-3.22 (-1.45%)

USD78.64B 48.79 34.81
HOLX Hologic Inc

-0.42 (-0.53%)

USD19.39B 12.84 8.15
RGEN Repligen Corporation

-1.96 (-1.28%)

USD8.57B 61.10 35.23
XRAY DENTSPLY SIRONA Inc

-0.40 (-1.04%)

USD8.13B 22.46 11.38
NVCR NovoCure Limited

-3.49 (-4.53%)

USD8.01B 1,480.87 3,651.48
MASI Masimo Corporation

-0.85 (-0.60%)

USD7.84B 36.48 22.65
AZTA Azenta Inc

-1.60 (-2.26%)

USD5.22B 2.35 418.21
ICUI ICU Medical Inc

-0.54 (-0.30%)

USD4.32B 96.92 32.28
QDEL Quidel Corporation

-0.85 (-0.84%)

USD4.29B 6.09 2.23
MMSI Merit Medical Systems Inc

-1.54 (-2.54%)

USD3.34B 70.93 24.01

ETFs Containing ATRC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -40.54% 37% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -40.54% 37% F 32% F
Trailing 12 Months  
Capital Gain -42.25% 55% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.25% 55% F 37% F
Trailing 5 Years  
Capital Gain 96.20% 70% C- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 96.20% 70% C- 80% B-
Average Annual (5 Year Horizon)  
Capital Gain 40.13% 70% C- 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.13% 70% C- 86% B
Risk Return Profile  
Volatility (Standard Deviation) 35.35% 73% C 44% F
Risk Adjusted Return 113.54% 97% A+ 98% A+
Market Capitalization 1.91B 69% D+ 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 36.84 46% F 25% F
Price/Book Ratio 4.37 29% F 19% F
Price / Cash Flow Ratio -138.86 97% A+ 90% A-
EV/EBITDA 29.17 52% F 20% F
Management Effectiveness  
Return on Equity 12.16% 74% C 72% C-
Return on Invested Capital 10.79% 68% D+ 77% C+
Return on Assets -4.68% 43% F 36% F
Debt to Equity Ratio 12.35% 65% D 70% C-
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 7.60 26% F 17% F
Short Percent 3.72% 49% F 43% F
Beta 1.19 45% F 42% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector